\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes MSCA Research Infrastructures Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment EIE Widening/SpreadingThe amended version of the Horizon Europe Main Work Programme 2021-2022 has been published on 10 May 2022. You can find the latest versions per subprogramme on the NCP Flanders website: Navigate to the respective subprogramme page and the link is situated in the right hand column of the page (under the section 'Work Programme & Calls').
The Commission provides a seperate document with the history of the changes introduced for each of the subprogrammes. You can find the 'History of Changes' document also on the respective subprogramme pages on our website, again in the right hand column (under the section 'Related Links'). This document allows you to quickly grasp which changes have been introduced as compared to the previous version.
Source: the Funding & Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
